Phase 3
Completed N=485
Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients
Source: ClinicalTrials.gov NCT03825380 ↗Enrolled (actual)
485
Serious AEs
0.6%
Results posted
Nov 2023
Primary outcomePrimary: Intra-Ocular Pressure — -9.67; -9.50 mmHg — p=0.453
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The purpose of this study is to assess the efficacy and safety of T4032 versus Lumigan.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Intra-Ocular Pressure |
-9.67; -9.50 | 0.453 |
Eligibility Criteria
Inclusion Criteria
- Informed consent signed and dated.
- Both eyes with diagnosed open-angle glaucoma or ocular hypertension
Exclusion Criteria
- History of trauma, infection, clinically significant inflammation within the 3 previous months.
- Uncontrolled diabetic patient.
- Pregnancy or breast feeding.
Data sourced from ClinicalTrials.gov (NCT03825380). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.